Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.64 Insider Own3.98% Shs Outstand59.20M Perf Week-9.18%
Market Cap227.35M Forward P/E- EPS next Y-0.42 Insider Trans24.15% Shs Float56.55M Perf Month32.19%
Income-37.54M PEG- EPS next Q-0.11 Inst Own61.25% Short Float3.63% Perf Quarter25.32%
Sales0.00M P/S- EPS this Y70.80% Inst Trans-1.08% Short Ratio3.48 Perf Half Y123.12%
Book/sh2.02 P/B1.91 EPS next Y-124.73% ROA-22.78% Short Interest2.05M Perf Year-62.67%
Cash/sh2.42 P/C1.59 EPS next 5Y- ROE-27.73% 52W Range1.42 - 11.97 Perf YTD9.97%
Dividend Est.- P/FCF- EPS past 5Y18.70% ROI-31.27% 52W High-67.75% Beta1.43
Dividend TTM- Quick Ratio6.44 Sales past 5Y0.00% Gross Margin- 52W Low171.83% ATR (14)0.30
Dividend Ex-Date- Current Ratio6.44 EPS Y/Y TTM39.98% Oper. Margin0.00% RSI (14)51.23 Volatility6.47% 7.87%
Employees10 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.25
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q63.55% Payout- Rel Volume0.73 Prev Close3.98
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume589.66K Price3.86
SMA201.55% SMA508.18% SMA200-15.40% Trades Volume429,630 Change-3.02%
Date Action Analyst Rating Change Price Target Change
Apr-03-24Upgrade Oppenheimer Perform → Outperform $10
Apr-02-24Resumed H.C. Wainwright Buy $10
Apr-27-22Resumed H.C. Wainwright Buy $15
Feb-08-21Initiated H.C. Wainwright Buy $26
Dec-16-20Initiated Berenberg Buy $32
Oct-30-20Initiated Jefferies Buy $24
Oct-16-20Initiated BTIG Research Buy $29
Sep-22-20Initiated Alliance Global Partners Buy $32
May-12-20Initiated Oppenheimer Outperform $12
Dec-04-18Initiated Citigroup Buy $23
Apr-18-24 07:00AM
Apr-06-24 06:37AM
Apr-04-24 12:36PM
Apr-03-24 02:58PM
Mar-28-24 07:00AM
01:21PM Loading…
Mar-27-24 01:21PM
Mar-13-24 02:33AM
Mar-06-24 09:40AM
Feb-06-24 07:00AM
Jan-04-24 07:00AM
Dec-19-23 07:27AM
Dec-18-23 04:01PM
Dec-06-23 11:55AM
09:00AM Loading…
Dec-05-23 09:00AM
Nov-27-23 04:07PM
Nov-01-23 10:34AM
Oct-18-23 08:30AM
Oct-17-23 10:13AM
Aug-28-23 10:22AM
Jul-20-23 09:55AM
Jul-06-23 07:00AM
Jun-29-23 07:00AM
Jun-28-23 04:01PM
Jun-27-23 12:03PM
Jun-26-23 04:01PM
07:00AM Loading…
Jun-23-23 07:00AM
Jun-21-23 09:34AM
Jun-16-23 10:26AM
Jun-15-23 02:52PM
Jun-14-23 04:01PM
Jun-02-23 07:00AM
May-07-23 07:30AM
May-04-23 07:00AM
Apr-13-23 07:00AM
Apr-06-23 07:00AM
Mar-30-23 07:00AM
Mar-16-23 07:00AM
Mar-11-23 02:59AM
Mar-09-23 11:05PM
Mar-02-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 03:22PM
Feb-23-23 07:00AM
Feb-22-23 05:26AM
Feb-16-23 07:00AM
Feb-09-23 07:00AM
Feb-07-23 07:00AM
Jan-12-23 06:37AM
Dec-21-22 07:00AM
Dec-13-22 01:37PM
Dec-01-22 08:00AM
Nov-29-22 08:00AM
Nov-10-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 01:45PM
Oct-26-22 08:00AM
Oct-06-22 12:23PM
Oct-05-22 04:05PM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-01-22 06:56AM
Aug-15-22 09:55AM
Aug-07-22 03:00AM
Aug-05-22 07:00AM
Aug-01-22 02:55PM
Jul-29-22 08:00AM
Jul-13-22 10:53AM
Jul-12-22 09:00AM
Jul-11-22 04:05PM
Jun-28-22 12:20PM
Jun-21-22 11:01AM
Jun-09-22 08:00AM
Jun-08-22 09:40AM
Jun-07-22 04:05PM
May-24-22 07:00AM
May-23-22 04:05PM
May-18-22 03:26PM
May-05-22 08:30PM
May-04-22 08:30AM
Apr-28-22 04:05PM
Apr-27-22 08:00AM
Apr-21-22 08:00AM
Apr-05-22 08:00AM
Mar-29-22 08:00AM
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 05 '24Buy4.7437,712178,7559,275,851Apr 08 05:32 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 04 '24Buy4.67140,281655,1129,238,139Apr 08 05:32 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 03 '24Buy4.09309,8471,267,2749,097,858Apr 03 05:22 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 02 '24Buy3.44186,051640,0158,788,011Apr 03 05:22 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 01 '24Buy3.258,37427,2168,601,960Apr 03 05:22 PM
Brady Todd CPresident and CEOMar 12 '24Sale3.0585,324260,2381,471,298Mar 12 08:01 PM
Machatha StephenChief Development OfficerMar 12 '24Sale3.1611,53736,503243,495Mar 12 08:04 PM
Brady Todd CPresident and CEOMar 11 '24Sale3.2797,914320,5211,556,622Mar 12 08:01 PM
Machatha StephenChief Development OfficerMar 11 '24Sale3.4118,23162,102255,032Mar 12 08:04 PM
Greenberg BruceSee RemarksMar 11 '24Sale3.4113,20144,968120,699Mar 12 08:07 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 18 '23Sale1.74306,499533,3088,593,586Oct 18 05:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 16 '23Sale1.602,450,0003,920,0008,900,085Oct 18 05:15 PM
Brady Todd CPresident and CEOSep 07 '23Option Exercise0.55273,058150,7281,728,343Sep 11 05:42 PM
Phillips Gary M.DirectorSep 07 '23Option Exercise0.555,4373,00114,812Sep 11 04:31 PM
Walker NealDirectorAug 22 '23Option Exercise0.559,6045,30115,854Aug 24 04:13 PM
Bronstein BenDirectorJun 27 '23Option Exercise0.559,6045,30128,248Jun 29 04:23 PM